Does Medicaid cover Ozempic, Wegovy and Zepbound?

Medicaid covers Ozempic for type 2 diabetes, the use it’s approved for, in every state, because federal rules require Medicaid to cover drugs for their approved uses. For weight loss, coverage of Ozempic, Wegovy, Zepbound and other GLP-1s is each state’s choice, and as of mid-October 2026 only 8 state programs cover them for obesity with prior authorization, plus Michigan and Virginia under strict limits.

Below is why the two answers differ, where every state stands, and what the CMS BALANCE model could change.

Why diabetes and weight loss get different answers

Under the Medicaid Drug Rebate Program, state Medicaid programs must cover nearly all FDA-approved drugs from participating manufacturers for medically accepted uses. Drugs used for weight loss are one of a small group of exceptions that states may leave out. So, as KFF puts it, covering GLP-1s for obesity is optional, while coverage for diabetes, cardiovascular disease and sleep apnea is required. Coverage is also required for children when medically necessary under Medicaid’s EPSDT benefit.

That makes the reason on your prescription decisive:

Scroll sideways to see the full table

States still manage required uses with diagnosis codes and prior authorization. California, for example, keeps Ozempic and Mounjaro on its drug list only with a type 2 diabetes diagnosis, and reviews Wegovy for heart disease and Zepbound for sleep apnea case by case (Medi-Cal Rx, April 6, 2026). Our guide to Zepbound for sleep apnea explains that route.

Medicaid GLP-1 coverage for weight loss, by state

This table comes from our state data, last checked October 17, 2026. It uses KFF’s January 2026 survey for most states and newer state notices compiled by The Rx Index (updated September 28, 2026), Michigan’s health department, Virginia Medicaid, Boston.com and the American Diabetes Association. The last column shows the date each status was checked. Each state links to its page, with the online programs that serve it.

Scroll sideways to see the full table

Every program that covers GLP-1s for obesity requires prior authorization or strict criteria, and managed care plans can add their own. Rules change often, so confirm with your state Medicaid office or plan before you count on coverage.

What changed between October 2025 and October 2026

That’s 7 states that have ended weight-loss coverage since late 2025. KFF links the cuts it counted to state budget pressure and the drugs’ cost.

The CMS BALANCE model

BALANCE is a voluntary CMS model in which CMS negotiates GLP-1 prices and coverage terms with drug makers on behalf of state Medicaid agencies. State Medicaid agencies can join from May 2026 through January 1, 2027, and Medicaid coverage for weight loss under the model can start as early as May 2026. People who get a GLP-1 through it also get a lifestyle support program from the manufacturer at no cost.

CMS is clear about the limits: coverage depends on which states and manufacturers take part, patients face the eligibility rules and prior authorization set in those negotiations, and the model “will not guarantee coverage for any individual.” Indiana announced on July 30, 2026 that it will join, but as of The Rx Index’s September 28 review, its start date and eligibility rules weren’t established. On the Medicare side, BALANCE won’t launch in 2027; the Medicare GLP-1 Bridge runs through December 31, 2027 instead. See our Medicare guide.

If your state doesn’t cover GLP-1s for weight loss

• Check for a required use. If you have type 2 diabetes, established heart disease with overweight or obesity, or moderate to severe sleep apnea with obesity, ask your clinician whether a prior authorization for that use fits your situation.
• Under 21. EPSDT requires coverage of medically necessary care for children and young adults, so a request may be reviewed even where adult weight-loss coverage has ended.
• If you also have Medicare. The Medicare GLP-1 Bridge charges eligible Part D enrollees $50 a month for Wegovy, Foundayo or the Zepbound KwikPen for weight loss.
• Paying cash. Manufacturer savings cards exclude Medicaid, but Novo Nordisk’s Ozempic offer page says people with government coverage can pay its self-pay price. As of October 27, 2026, that’s $199 for the first 2 fills, then $349 a month for Ozempic at 0.25 mg to 1 mg; the Wegovy pill costs $149 to $299 at NovoCare, and Zepbound $299 to $449 at LillyDirect with refills within 45 days.

Online programs list lower prices for compounded drugs: at the 26 programs we rank, as of November 2026, compounded semaglutide costs $65 to $299 a month and compounded tirzepatide $85.58 to $378.08. A compounded GLP-1 is not Ozempic, Wegovy or Zepbound, and not a generic of them. A compounding pharmacy prepares it, it isn’t FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness or quality (FDA). Our guide to GLP-1s without insurance compares every cash option, and our cheapest GLP-1 rankings list programs by price.

The bottom line

Medicaid covers Ozempic and other GLP-1s for type 2 diabetes in every state, and it must cover Wegovy for heart risk and Zepbound for sleep apnea. Coverage for weight loss alone is a state decision, and in mid-October 2026 only Delaware, Kansas, Minnesota, Mississippi, Missouri, North Carolina, Tennessee and Wisconsin offer it with prior authorization, with Michigan and Virginia under strict limits.

Find your state in the table above, check whether another approved use applies to you, and ask your state Medicaid office or plan about prior authorization before you pay cash. Our insurance coverage guide covers commercial plans and Medicare too.